Drug intelligence / Profile preview

UDI-001

Development stage: Phase 2
Lead developer: Rohto Pharmaceutical
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

UDI-001 is an allogeneic cell therapy product composed of human umbilical cord-derived mesenchymal stem cells (UC-MSCs). Developed by Rohto Pharmaceutical, the product is manufactured using a proprietary automated culture system to ensure consistency and scalability. UDI-001 is primarily being investigated for the treatment of pediatric cerebral palsy, specifically in patients with periventricular leukomalacia (PVL). The therapeutic rationale involves the ability of UC-MSCs to migrate to sites of brain injury, where they may promote neuroprotection, reduce neuroinflammation, and stimulate endogenous repair mechanisms through the secretion of various cytokines and growth factors.

Other names: umbilical cord-derived mesenchymal stem cellsUC-MSCs

Beyond the preview

Go deeper on UDI-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UDI-001.

Explore the full profile